Giuseppe MichieliImpaired neutralizing #antibody #efficacy of #tixagevimab-cilgavimab 150+150 mg as pre-exposure #prophylaxis against #Omicron #BA5. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: https://doi.org/10.1016/j.jcv.2023.105584 #reseach #science #medicine #mAbs #betacoronavirus #sarbecovirus #covid19
''To date, #tixagevimab-cilgavimab cannot be considered a substitute for #vaccination but may be a useful supporting #therapy if the recommended dose for pre-exposure prophylaxis is doubled.''
#Breakthrough #SARS-CoV-2 #Infections in the PROVENT #Prevention Trial Were Not Associated with AZD7442 (#Tixagevimab/Cilgavimab) Resistant Variants https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad210/7191107?rss=1
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated with AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
AbstractBackground. We report spike protein-based lineage and AZD7442 (tixagevimab/cilgavimab) neutralizing activity of SARS-CoV-2 variants identified from brea
#Genotypic and Predicted #Phenotypic #Analysis of #SARS-COV-2 #Omicron #Subvariants in Immunocompromised Patients with #COVID19 Following #Tixagevimab-Cilgavimab Prophylaxis https://www.sciencedirect.com/science/article/pii/S1386653223000057?dgcid=rss_sd_all
#Safety, Tolerability and Pharmacokinetics of Half-Life Extended #SARS-CoV-2 Neutralizing Monoclonal #Antibodies #AZD7442 (#Tixagevimab / #Cilgavimab) in Healthy Adults https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad014/6997870?rss=1
Safety, Tolerability and Pharmacokinetics of Half-Life Extended SARS-CoV-2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab/Cilgavimab) in Healthy Adults
A single 300-mg intramuscular dose of AZD7442 (150-mg each of tixagevimab/cilgavimab) exhibited an approximate 90-day half-life, was well tolerated in a phase 1
AltreconomiaBrevetti e pillole amare: l’Ue continua a difendere Big Pharma, non solo sui vaccini https://altreconomia.it/brevetti-e-pillole-amare-lue-continua-a-difendere-big-pharma-non-solo-sui-vaccini/ #CorporateEuropeObservatory #immunosoppressore #Approfondimento #astrazeneca #monoclonali #Tixagevimab #Tocilizumab #Sotrovimab #anticorpi #covid-19 #pfizer #covid #Merck #Roche #GSK
Brevetti e pillole amare: l'Ue continua a difendere Big Pharma, non solo sui vaccini
Dopo aver negato ai Paesi a basso reddito un accesso equo ai vaccini, l’Unione europea è pronta a fare lo stesso con i medicinali per il trattamento del Covid-19, privilegiando gli interessi di Pfizer, Merck, Roche, AstraZeneca e GSK e tagliando fuori milioni di persone. La denuncia del Corporate europe observatory